Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus
NCT ID: NCT07304284
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
2824 participants
INTERVENTIONAL
2025-10-31
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Immunogenicity of a New Formulation of Euvichol®
NCT02502331
Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
NCT04984408
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
NCT06803342
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
NCT02094586
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults
NCT04710303
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 2824 participants aged 1-45 years will be enrolled in the study in 4 cohorts: cohort A (1272 healthy adults aged 18-45 years), cohort AA (160 people living with HIV (PLWH) aged 18-45 years), cohort B (696 healthy children aged 6-17 years), and cohort C (696 healthy children aged 1-5 years). Participants in cohort A will be randomized into 4 arms to receive either one of the 3 lots of Biovac OCV-S or to receive the comparator Euvichol®-Plus in 1:1:1:1 ratio. Participants in cohorts AA, B and C will each be randomized into 2 arms to receive either Biovac OCV-S or Euvichol®-Plus in 3:1 ratio.
Each of the study participants will receive the assigned investigational product Biovac OCV-S or Euvichol®-Plus given orally in 2 doses at 2 weeks interval and will be followed up for safety and immunogenicity at specific time points. Each participant will be in the study for approximately 27 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A1: Biovac OCV-S
Biovac OCV-S (Lot 1), HIV Negative Group, 18-45 years
Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine)
Two doses (1.5mL) at two weeks interval given orally.
Arm A2: Biovac OCV-S
Biovac OCV-S (Lot 2), HIV Negative Group, 18-45 years
Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine)
Two doses (1.5mL) at two weeks interval given orally.
Arm A3: Biovac OCV-S
Biovac OCV-S (Lot 3), HIV Negative Group, 18-45 years
Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine)
Two doses (1.5mL) at two weeks interval given orally.
Arm A4: Euvichol®-Plus
Euvichol®-Plus, HIV Negative Group, 18-45 years
Active Comparator, Euvichol®-Plus
Two doses (1.5mL) at two weeks interval given orally.
Arm B1: Biovac OCV-S
Biovac OCV-S, HIV Negative Group, 6-17 years
Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine)
Two doses (1.5mL) at two weeks interval given orally.
Arm B2: Euvichol®-Plus
Euvichol®-Plus, HIV Negative Group, 6-17 years
Active Comparator, Euvichol®-Plus
Two doses (1.5mL) at two weeks interval given orally.
Arm C1: Biovac OCV-S
Biovac OCV-S, HIV Negative Group, 1-5 years
Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine)
Two doses (1.5mL) at two weeks interval given orally.
Arm C2: Euvichol®-Plus
Euvichol®-Plus, HIV Negative Group, 1-5 years
Active Comparator, Euvichol®-Plus
Two doses (1.5mL) at two weeks interval given orally.
Arm AA1: Biovac OCV-S
Biovac OCV-S, People living with HIV, 18-45 years
Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine)
Two doses (1.5mL) at two weeks interval given orally.
Arm AA2: Euvichol®-Plus
Euvichol®-Plus, People living with HIV, 18-45 years
Active Comparator, Euvichol®-Plus
Two doses (1.5mL) at two weeks interval given orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine)
Two doses (1.5mL) at two weeks interval given orally.
Active Comparator, Euvichol®-Plus
Two doses (1.5mL) at two weeks interval given orally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants/Parent(s)/Legally Authorized Representative (LAR) willing to provide informed consent/assent
3. HIV negative
4. Not pregnant or lactating
1. PLWH adults aged 18 to 45 years at consent
2. Participants on anti-retroviral (ARV) therapy with CD4 counts \>350 and viral loads that are undetectable.
3. Not pregnant or lactating
Exclusion Criteria
2. Individuals with major congenital abnormalities
3. Known history of immune function disorders including immunodeficiency diseases (known HIV infection in healthy participant cohorts) or other immune function disorders (all cohorts).
4. Use of systemic steroids within past 6 months (\>10 mg/day prednisone equivalent for periods exceeding 2 consecutive weeks), or receive chemotherapy, radiation therapy or other immunosuppressive drugs within the past 6 months.
5. Behavioral or cognitive impairment, chronic substance abuse, or psychiatric disease or neurological disorders.
6. Individuals with a known bleeding disorder.
7. Receipt of blood, blood-derived products, or immunoglobulin products in the past 3 months.
8. Individuals who have received other vaccines from 4 weeks prior to or within 4 weeks after any dose of the investigational product.
9. Individuals with active or previous Vibrio cholerae infection.
10. Individuals with receipt of a cholera vaccine in the past 5 years.
1 Year
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioVac
UNKNOWN
Medical Research Council, South Africa
OTHER
International Vaccine Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tarun Saluja, MD
Role: PRINCIPAL_INVESTIGATOR
International Vaccine Institute
Glenda Gray, MD
Role: PRINCIPAL_INVESTIGATOR
Medical Research Council, South Africa
Julia Lynch, MD
Role: STUDY_DIRECTOR
International Vaccine Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Synergy Biomed Research Institute
Durban, Eastern Cape, South Africa
Perinatal HIV Research Unit (PHRU)
Johannesburg, Gauteng, South Africa
Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit
Johannesburg, Gauteng, South Africa
SAMRC Chatworth CRS
Durban, KwaZulu-Natal, South Africa
SAMRC Isipingo CRS
Durban, KwaZulu-Natal, South Africa
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Dr. Naveena D'Cor Project Technical Lead / Study Medical Monitor, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IVI BIOVAC OCV-S 001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.